当前位置: 首页 >> 检索结果
共有 21101 条符合本次的查询结果, 用时 4.7021822 秒

321. Correction to Lancet Rheumatol 2024; 6: e237-46.

来源: Lancet Rheumatol. 2026年8卷2期e83页

322. Sjögren's Hands-On Practice Exchange (SHAPE): a qualitative, expert opinion project in Sjögren's disease clinical practice.

作者: Emily Gregg.;Charlotte Graham.;Deborah Watkins.;Viviam Canon Garcia.;Rachael McCool.
来源: BMC Rheumatol. 2025年10卷1期4页
Sjögren’s disease (SjD) is a multifaceted, systemic autoimmune disease with substantial clinical heterogeneity. The objective of this study was to conduct a qualitative expert opinion exercise to explore how SjD is assessed, evaluated and managed in international clinical practice.

323. Fibroblast heterogeneity in 2025.

作者: Adam P Croft.;Annie Hackland.
来源: Nat Rev Rheumatol. 2026年22卷2期86-88页

324. Progress in mechanisms and therapy for fibromyalgia.

作者: Hance Clarke.;Mary-Ann Fitzcharles.
来源: Nat Rev Rheumatol. 2026年22卷2期84-85页

325. Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits.

作者: Laura C M Schenning.;Marieke van Onna.;Sander W Tas.
来源: Lancet Rheumatol. 2026年8卷3期e228-e231页
Glucocorticoid pulse therapy is commonly prescribed by rheumatologists worldwide for a wide variety of serious and potentially life-threatening diseases. Pulse therapy also has the potential to lower the cumulative glucocorticoid burden, which has already been proven in systemic lupus erythematosus and giant cell arteritis. The standard practice in rheumatology is to administer this therapy intravenously, but current literature suggests that oral methylprednisolone is a non-inferior option for clinical outcomes and safety. Integrating oral methylprednisolone pulse therapy into rheumatological practice might have considerable benefits, not only for patients but also for society as a whole. In this Viewpoint, we provide a review of oral methylprednisolone pulse therapy covering pharmacology, safety, patient preference, sustainability, and its possible use in rheumatology practice. We aim to increase awareness among rheumatologists of the potential use of oral glucocorticoid pulse therapy as this modest change in clinical practice has major benefits.

326. The risk factors of cerebral small vessel disease in patients with Systemic Lupus Erythematosus.

作者: Junjun Sun.;Heng Wang.;Xiaoyan Xu.;Linchen Liu.
来源: BMC Rheumatol. 2025年10卷1期7页
Cerebral small vessel disease (CSVD) imposes a significant burden on patients with systemic lupus erythematosus (SLE) and adversely impacts their health.

327. Mechanistic link uncovered between EBV infection and SLE.

作者: Jessica McHugh.
来源: Nat Rev Rheumatol. 2026年22卷2期73页

328. Rethinking obesity, immunity, and the promise of anti-obesity therapies in PsA.

作者: Francesco Ciccia.;Ennio Lubrano.;Roberto Caporali.
来源: Rheumatology (Oxford). 2026年65卷3期

329. Juvenile dermatomyositis as a rare paraneoplastic manifestation of nasopharyngeal carcinoma.

作者: Merve Kutlar Tanıdır.;Batuhan Küçükali.;Nuran Belder.;Çisem Yıldız.;Nihal Karaçayır.;Büşra Acun.;Faruk G Pınarlı.;Deniz Gezgin Yıldırım.;Sevcan A Bakkaloğlu.
来源: Rheumatology (Oxford). 2026年65卷2期

330. Gut microbiome-metabolome dysregulation in systemic sclerosis: a multi-omics study.

作者: Qi-Cen Yao.;Da-Ya Zhang.;Yi-Ping Du.;Chen Chen.;Yan-Ting Lv.;Da Li.;Yi-Xi Xing.;Xia-Yu Xu.;Qian-Qi Lin.;Wen-Feng Tan.;Fei-Hu Bai.
来源: Rheumatology (Oxford). 2026年65卷1期
The interplay between the gut microbiome (GM), plasma metabolites and systemic sclerosis (SSc) has not been systematically studied. We hypothesized that disruption at the GM-metabolome interface contributes to the pathogenesis of SSc. This study aims to investigate the faecal microbiome composition and plasma metabolite profiles in SSc patients.

331. EBV and SLE: causal or concurrence?

作者: The Lancet Rheumatology.
来源: Lancet Rheumatol. 2026年8卷1期e1页

332. Lengthened telomere length in peripheral blood leukocytes in patients with rheumatoid arthritis complicated with airway disease.

作者: Takashi Higuchi.;Shomi Oka.;Kota Shimada.;Shinichiro Tsunoda.;Satoshi Ito.;Misuzu Fujimori.;Tadashi Nakamura.;Michita Suzuki.;Koichiro Saisho.;Satoshi Shinohara.;Toshihiro Matsui.;Kiyoshi Migita.;Shouhei Nagaoka.;Shigeto Tohma.;Hiroshi Furukawa.
来源: BMC Rheumatol. 2025年10卷1期6页
Patients with rheumatoid arthritis (RA) frequently have complications including chronic lung diseases (CLDs) consisting of airway disease (AD) or interstitial lung disease (ILD) that confer a poor prognosis. Peripheral blood leukocyte telomere length is shortened in RA with ILD. Previous studies reported rare variants in telomerase genes that were deleterious were more frequent in RA with ILD compared with controls. However, these studies were conducted in European populations. Here, we investigated associations of telomere length with ILD or AD in Japanese RA.

333. Overlapping macrophage immune profiles in polymyalgia rheumatica and giant cell arteritis.

作者: Anqi Zhang.;William F Jiemy.;Yannick van Sleen.;Shuang Xu.;Maria Sandovici.;Wayel H Abdulahad.;Arjan Diepstra.;Sandra Hein.;Jacoba C Graver.;Peter Heeringa.;Bhaskar Dasgupta.;Elisabeth Brouwer.;Kornelis S M van der Geest.
来源: Rheumatology (Oxford). 2026年65卷2期
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related chronic inflammatory diseases in which macrophages play a central role in the pathogenesis. This study compared macrophage-related immune profiles in subacromial bursal tissues affected by PMR and temporal arteries affected by GCA to identify shared therapeutic targets.

334. Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome.

作者: Oreola Donini.;Bercemhan Sulu.;Christopher Pullion.;Adam Rumage.;Richard Straube.;Christopher Schaber.;Gülen Hatemi.
来源: Rheumatology (Oxford). 2026年65卷2期
The study was designed to obtain a preliminary assessment of the safety and efficacy of SGX945 (dusquetide) for the treatment of aphthous oral and genital ulcers in Behçet's syndrome.

335. Real-world experience of anifrolumab in 30 patients with refractory DM: a multicentre-multidisciplinary retrospective study.

作者: Míriam Retuerto-Guerrero.;Clara Moriano Morales.;Ana Pareja-Martínez.;Natalia Molina-Esteban.;Jose Puig-Buendia.;Concepción Postigo Llorente.;Ana Lopez-Ceron Cofiño.;Julia Martínez-Barrio.;Paola Vidal-Montal.;Elena Sendagorta Cudos.;Luisa Martos Cabrera.;Guillermo González Arribas.;Jaime Calvo Alén.;Juan Ramón De Dios Jiménez de Aberasturi.;Juan María Blanco Madrigal.;Javier Bachiller Corral.;Alejandro Claudio Oliva.;Paloma Vela Casasempere.;Maria Castellanos Gonzalez.;Maria Concepción Fito Manteca.;Tania Marusia Capusan.;Carmen Ordás Calvo.;Daniel Ramos Rodríguez.;Alejandro Sanchez Herrero.;Luis Ortega-Valín.;Elvira Díez Álvarez.
来源: Rheumatology (Oxford). 2026年65卷2期
To assess real-world outcomes of anifrolumab (ANI) in refractory systemic DM.

336. Advances in understanding preclinical rheumatoid arthritis and prospects for prevention.

作者: Carol A Hitchon.;Hani S El-Gabalawy.
来源: Nat Rev Rheumatol. 2026年22卷2期82-83页

337. Comment on: Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with rheumatoid arthritis: a target trial emulation study.

作者: Hannah Khan.
来源: Rheumatology (Oxford). 2026年65卷2期

338. Prevalence, distribution and associations of the scleroderma capillaroscopic patterns: new insights from the Italian SPRING-SIR registry.

作者: Rossella De Angelis.;Clodoveo Ferri.;Edoardo Cipolletta.;Valeria Riccieri.;Marco Di Battista.;Gianluigi Bajocchi.;Silvia Bellando-Randone.;Cosimo Bruni.;Martina Orlandi.;Giovanni Zanframundo.;Roberta Foti.;Giovanna Cuomo.;Alarico Ariani.;Edoardo Rosato.;Gemma Lepri.;Francesco Girelli.;Elisabetta Zanatta.;Silvia Laura Bosello.;Ilaria Cavazzana.;Francesca Ingegnoli.;Maria De Santis.;Fabio Cacciapaglia.;Giuseppe Murdaca.;Giuseppina Abignano.;Giorgio Pettiti.;Alessandra Della Rossa.;Maurizio Caminiti.;Anna Maria Iuliano.;Giovanni Ciano.;Lorenzo Beretta.;Gianluca Bagnato.;Ennio Lubrano.;Ilenia De Andres.;Luca Idolazzi.;Marta Saracco.;Cecilia Agnes.;Corrado Campochiaro.;Marco Fornaro.;Federica Lumetti.;Amelia Spinella.;Emanuele Cocchiara.;Giacomo De Luca.;Veronica Codullo.;Elisa Visalli.;Carlo Iandoli.;Antonietta Gigante.;Greta Pellegrino.;Erika Pigatto.;Maria Grazia Lazzaroni.;Enrico De Lorenzis.;Francesca Motta.;Antonio Tonutti.;Gianna Mennillo.;Giuseppa Pagano-Mariano.;Federica Furini.;Licia Vultaggio.;Simone Parisi.;Clara Lisa Peroni.;Gerolamo Bianchi.;Enrico Fusaro.;Gian Domenico Sebastiani.;Marcello Govoni.;Salvatore D'Angelo.;Franco Cozzi.;Franco Franceschini.;Serena Guiducci.;Dilia Giuggioli.;Lorenzo Dagna.;Andrea Doria.;Carlo Salvarani.;Florenzo Iannone.;Marco Matucci-Cerinic.; .
来源: Rheumatology (Oxford). 2026年65卷1期
To assess the relationship between disease duration and the prevalence/distribution of nailfold videocapillaroscopy (NVC) patterns, named according to the current classification as 'early', 'active' and 'late', in a large cohort of systemic sclerosis (SSc) patients.

339. Lowering glucocorticoid dose in lupus nephritis: by response or by protocol?

作者: Guillermo Ruiz-Irastorza.;Amaia Osorio.
来源: Rheumatology (Oxford). 2026年65卷2期

340. Diffuse alveolar haemorrhage in antiphospholipid syndrome: a French series of 26 patients.

作者: Vincent Grobost.;Mélanie Ramos.;Cécile Yelnik.;Marie De Antonio.;Nathalie Morel.;Jean-François Viallard.;Eric Hachulla.;Marc André.;Anne-Marie Milesi Lecat.;Sébastien Trouillier.;Maxime Samson.;Christian Lavigne.;Aurelien Lebreton.;Marc Lambert.;Marc Ruivard.;Nathalie Costedoat-Chalumeau.
来源: Rheumatology (Oxford). 2026年65卷3期
Diffuse alveolar haemorrhage (DAH) is a rare and poorly understood manifestation of antiphospholipid (AP) syndrome (APS). This study describes the clinical presentation, treatment and prognosis of DAH in APS with or without catastrophic APS (CAPS).
共有 21101 条符合本次的查询结果, 用时 4.7021822 秒